Heterocyclic Compounds

Matches 851 - 900 out of 9,413	< 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 >

Document	Document Title
WO/2021/047555A1	PREPARATION OF AROMATIC HETEROCYCLIC DERIVATIVE AS IMMUNOMODULATOR AND APPLICATION THEREOF Provided are the preparation of an aromatic heterocyclic derivative as an immunomodulator and an application thereof. Specifically, provided is a compound represented by formula I below, or an optical isomer, hydrate, solvate, or pharmac...
WO/2021/043850A1	TRICYCLIC JANUS KINASE (JAK) INHIBITORS AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES The present invention relates to compounds of formula (1) or (2), wherein R1 and R3 are purine or a purine analog and R2 and R4 are a small functional group. The invention also relates to intermediates of the synthesis of compounds of fo...
WO/2021/042890A1	HETEROCYCLIC COMPOUND AND APPLICATION THEREOF AS TRK KINASE INHIBITOR A heterocyclic compound shown in formula I and application thereof as a Trk kinase inhibitor.
WO/2021/041861A1	N-(2-AMINOPHENYL)-PROP-2-ENAMIDE DERIVATIVES, AND USES THEREOF IN THE TREATMENT OF CANCER Provided herein are N-(2-aminophenyl)-prop-2-enamide derivatives, such as those of Formula (I), methods for the synthesis thereof, and uses thereof in the treatment of cancer, such as SALL4-expressing cancer, in a cell or subject in need...
WO/2021/039961A1	RING-FUSED PYRAZOLE DERIVATIVE Provided are a ring-fused pyrazole derivative, which is useful as a therapeutic agent and/or a preventive agent for diseases associated with Nav1. 1 and various central nervous system diseases, and/or a pharmaceutically acceptable salt t...
WO/2021/032323A1	FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES The present invention discloses compounds according to Formula I, wherein A, B, R1, R2, and Cy are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmace...
WO/2021/028382A1	[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES The present invention covers [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds of general formula (I) in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, methods of preparing said compounds, intermediate compounds useful f...
WO/2021/027943A1	PYRIMIDINOPYRIDAZINONE DERIVATIVE AND MEDICAL USE THEREOF A pyrimidinopyridazinone derivative and a medical use thereof. The derivative has a structure represented by general formula (I). The present invention also relates to a preparation method for the compound of general formula (I), a pharm...
WO/2021/030142A1	THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF The present disclosure relates generally to compounds that bind to Acetyl-CoA Carboxylase (ACC) and act as inhibitors of ACC. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatmen...
WO/2021/027172A1	HOLE TRANSPORT MATERIAL AND PREPARATION METHOD THEREFOR, AND ORGANIC LIGHT-EMITTING DEVICE Disclosed is a hole transport material with a structural general formula of (A), wherein group R is any one of a carbazole group and a derivative group thereof, a diphenylamine group and a derivative group thereof, a phenoxazine group an...
WO/2021/028854A1	PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS The present invention provides a compound of Formula (I): (I) or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides p...
WO/2021/027911A1	NOVEL SPIROCYCLIC K-RAS G12C INHIBITOR The present invention relates to a spirocyclic compound and a preparation method therefor and use thereof, in particular to a compound represented by formula (1) and a preparation method therefor, and use of the compound of formula (1) a...
WO/2021/023209A1	NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUNDS, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF The present invention relates to the field of medicinal chemistry, and relates in particular to nitrogen-containing polycyclic fused ring compounds represented by formula I, and a pharmaceutical composition thereof, a preparation method ...
WO/2021/024039A1	COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN AND DEPENDANCE DISORDERS Provided herein are (e.g., controlled release) compositions for the treatment of acute or chronic diseases or disorders. Described herein are processable opioid conjugates. Also described herein are compositions and methods for the treat...
WO/2021/023204A1	USE OF CDK4/6 INHIBITOR IN COMBINATION WITH MULTI-TARGET TYROSINE KINASE INHIBITOR IN PREPARING MEDICAMENT FOR TREATING TUMOR Disclosed is a use of a CDK4/6 inhibitor in combination with a multi-target tyrosine kinase inhibitor in preparing a medicament for treating a tumor. Specifically, the CDK4/6 inhibitor is a compound represented by formula (I) or a pharma...
WO/2021/018287A1	SPIROAROMATIC COMPOUND, PREPARATION AND APPLICATION THEREOF Provided is a compound with inhibitory activity on SHP2, a preparation method therefor, and a use thereof. Specifically, provided is a compound represented by formula (I), a pharmaceutically acceptable salt thereof, a solvate, an isotopi...
WO/2021/017069A1	PYRROLOPYRAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE Disclosed are a pyrrolopyrazole derivative, a preparation method therefor, and an application thereof in medicine. Specifically, the present invention relates to a class of pyrrolopyrazole derivatives represented by general formula (I), ...
WO/2021/017114A1	CYCLIC COMPOUND AND USE THEREOF, AND ELECTRONIC DEVICE A cyclic compound and a use thereof, and an electronic device. The cyclic compound comprises at least compounds represented by formulas 001-011, the cyclic compound has good thermal stability and has a matching LUMO energy level to an ad...
WO/2021/020363A1	HETEROCYCLIC COMPOUND Provided is a compound which has a glucosylceramide synthase-inhibiting activity and is expected to be useful as a prophylactic or therapeutic agent for a lysosomal storage disease (e.g., Gaucher disease, Fabry disease, GM1-gangliosidosi...
WO/2021/021775A1	SOLID STATE FORMS OF RISDIPLAM AND PROCESS FOR PREPARATION THEREOF The present disclosure encompasses solid state forms of Risdiplam, including crystalline polymorphs of Risdiplam, processes for preparation thereof, and pharmaceutical compositions thereof.
WO/2021/014365A1	MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF Disclosed are macrocyclic compounds having the general Formula (I) or (II) and their tautomeric forms, stereoisomers, pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof, and their combination with suitable medicam...
WO/2021/011913A1	TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE The present disclosure relates to bifunctional compounds, which find utility as modulators of tan protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand whi...
WO/2021/008455A1	RET SELECTIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF Provided are an RET selective inhibitor, a preparation method therefor and a use thereof. Provided are a compound of formula (I) and a pharmaceutically acceptable salt, a solvent, a polymorph or an isomer thereof, a pharmaceutical compos...
WO/2021/007882A1	ORGANIC COMPOUND OF NITROGEN-CONTAINING HETEROCYCLE, AND ORGANIC ELECTROLUMINESCENT DEVICE The present invention relates to an organic compound of a nitrogen-containing heterocycle, and an organic electroluminescent device. The structural general formula of the organic compound of the nitrogen-containing heterocycle is shown i...
WO/2021/009212A1	ANTIBACTERIAL QUINOLONE DERIVATIVES The invention relates to compounds of Formula I which are useful as antibacterial agents in medicine.
WO/2021/009365A1	BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING A compound of formula (I): wherein: Y is (CH2)n, where n is from 2 to 4; W1 and W11 are independently selected from OH and ORP, where RP is Me or Et.
WO/2021/007269A1	BICYCLIC HETEROCYCLES AS FGFR INHIBITORS The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 enzyme and are useful in the treatment of FGFR3-associated diseases such as cancer, Formula (I).
WO/2021/005034A1	NEW HETEROCYCLIC COMPOUNDS The invention provides new heterocyclic compounds having the general formula (I) wherein R1, R2, X, and Y are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the comp...
WO/2021/003157A1	EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X...
WO/2021/001330A1	HETEROCYCLIC MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS The application relates to heterocyclic compounds of the general formula (I), a process for their preparation, pharmaceutical compositions containing them and their medical use. The compounds act as inhibitors of monoacylglycerol lipase ...
WO/2021/001739A1	TRANSLATIONAL ENHANCERS AND RELATED METHODS The present disclosure relates to novel translational enhancers comprising an eukaryotic initiation factor 4E (eIF4E) ligand attached to a dinucleotide. The present disclosure also relates to RNA molecules (e.g., mRNAs) comprising the no...
WO/2021/000242A1	THIENOPYRIMIDINE DERIVATIVES HAVING STEREO CONFIGURATIONS AND USE THEREOF IN MEDICINE Thienopyrimidine derivatives having stereo configurations and use thereof in medicine. Also comprised are pharmaceutical compositions of the compounds. The compounds or pharmaceutical compositions may be used to inhibit acetyl-CoA carbox...
WO/2020/264292A1	CXCR4 INHIBITORS AND USES THEREOF The present invention relates to compounds and methods of inhibiting C-X-C receptor type 4 (CXCR4). The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using s...
WO/2020/259601A1	SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF The disclosure provides novel substituted fused heteroaromatic compounds as represented in Formula I, wherein A1-A6 and R1-R4 are defined herein. The compounds of Formula I are kinase inhibitors, especially ATR kinase inhibitors. Therefo...
WO/2020/263980A1	IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE This invention relates to Imidazo[l,2-a]pyridinyl Derivatives of formula (I), or pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. T...
WO/2020/264420A1	HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF Compounds are provided having the structure of Formula (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, tautomer, isotope, or salt thereof, wherein A, X, R3, R5, R6, R7, R8, Y2, Y4, Y6, Y7, Y8, Y9, m, and n are as...
WO/2020/259556A1	AZAINDOLE PYRAZOLE COMPOUNDS AS CDK9 INHIBITORS Azaindole pyrazole compounds as CDK9 inhibitors, in particular, compounds as represented by formula (I), pharmaceutically acceptable salts thereof, and isomers thereof, and an application of the compounds as represented by formula (I), t...
WO/2020/259724A2	PYRAZOLONE AND PYRIMIDINE COMPOUND, AND PREPARATION METHOD AND USE THEREFOR Disclosed in the present invention are a pyrazolone and pyrimidine compound, and a preparation method and a use therefor. Provided in the present invention is a pyrazolone and pyrimidine compound as in formula (I), said compound having b...
WO/2020/263967A1	2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE This invention relates to 2H-indazole Derivatives of formula (I'), or pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. The inventio...
WO/2020/259432A1	KRAS-G12C INHIBITOR The present invention provides a G12C mutant K-Ras protein irreversible inhibitor. Also disclosed are the G12C mutant K-Ras protein irreversible inhibitor and a preparation method and use thereof.
WO/2020/253458A1	CDK KINASE INHIBITOR Disclosed in the present application are a compound of general formula (I) capable of being used as a CDK kinase (in particular, CDK4/6 kinase) inhibitor, and a salt thereof, wherein all variates are defined as the present text. The comp...
WO/2020/249663A1	NOVEL SPIROBICYCLIC INTERMEDIATES The present invention relates to novel spirobicyclic intermediates useful in the synthesis of spirobicyclic nucleoside analogues.
WO/2020/248972A1	HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF (I) Disclosed herein are compounds of formula I, and/or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate thereof; and therapeutic uses of these compounds, which are inhibitors of rearranged during transf...
WO/2020/252222A1	PROGRANULIN MODULATORS AND METHODS OF USING THE SAME Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemporal dementia (FTD).
WO/2020/244614A1	PYRROLOPYRIMIDINE COMPOUND AND USE THEREOF The present invention relates to a pyrrolopyrimidine compound used as a JAK inhibitor, and the use thereof in the preparation of a drug for treating a JAK1- and/or JAK2-associated disease; and specifically relates to a compound represent...
WO/2020/246487A1	COMPOUNDS HAVING DISPIRO DIKETOPIPERAZINE STRUCTURE The present invention provides anticancer agents that have a novel structure and demonstrate highly selective effects on cancer cells.　Compounds that have a dispiro diketopiperazine structure that is represented by general formula (I),...
WO/2020/244539A1	PYRIDONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF A pyridone derivative, a preparation method therefor, and pharmaceutical application thereof. In particular, the present invention relates to a pyridone derivative represented by general formula (I), a preparation method for the derivati...
WO/2020/244570A1	PORPHIN PHOTOSENSITIZER TARGETING FOLIC ACID AND COUPLED TO DIFFERENT CONNECTION CHAINS AND SYNTHESIS AND APPLICATION OF PORPHIN PHOTOSENSITIZER Disclosed are a photosensitizer represented by general formula (I), a preparation method for the photosensitizer and an application thereof in tumor photodynamic therapy and tumor imaging diagnosis. In the photosensitizer, folic acid as ...
WO/2020/238900A1	DNA-DEPENDENT PROTEIN KINASE INHIBITOR Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are useful as DNA-PK inhibitors. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (I), and metho...
WO/2020/243376A1	HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER The present disclosure provides for compounds according to Formula I, Formula II, and their pharmaceutically acceptable salts, tautomers, and/or isotopologues as described in the disclosure. The compounds are inhibitors of methionine ade...

Matches 851 - 900 out of 9,413	< 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 >